A Phase 1, Open Label, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- FDL176 & FDL169 coadministration
- Conditions
- Cystic Fibrosis
- Sponsor
- Flatley Discovery Lab LLC
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Pharmacokinetic parameters, Cmax
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This is an 2-part study. Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration of FDL169. Part 2 will assess the safety, tolerability and pharmacokinetics of repeated doses of FDL176 with and without co-administration of FDL169 .
Detailed Description
This is an open-label, non-randomised, single-sequence 2-part study. Enrolment into Part 2 of the study will begin after Part 1 is complete, and a review of safety and pharmacokinetic data has been completed.Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration of FDL169. Part 2 will assess the safety, tolerability and pharmacokinetics of repeated doses of FDL176 once daily (QD) with and without co-administration of FDL169.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy males or non-pregnant, non-lactating healthy females.
- •Body mass index of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator.
- •Must agree to follow the study's contraception requirement
Exclusion Criteria
- •Prior or ongoing medical condition, medical history, physical findings, ECG findings or laboratory abnormality that, in the Investigator's (or delegate's) opinion, could adversely affect the safety of the subject or would place the subject at increased risk.
- •History of long QT syndrome and/or QT corrected according to Fridericia's formula (QTcF) interval (\>450 msec) or QTcF \>450 msec at Screening or Day -
- •Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active.
- •Use of any prescription drugs within 14 days or 5 half-lives (whichever is longer) before the first dose of IMP, unless in the opinion of the Investigator (or delegate) .
- •Use of any non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) before the first dose of IMP.
- •Use of any prescription and non-prescription medications that are strong inhibitors or moderate inducers of cytochrome P450 3A, within 28 days before the first dose of IMP.
- •Participation in another clinical trial involving receipt of an IMP within the past 90 days.
- •Prior exposure to FDL169 or FDL176
- •Alkaline phosphatase, aspartate aminotransferase and/or alanine aminotransferase \>1.5 x upper limit of normal (ULN) at screening.
- •Serum creatinine or total bilirubin \>1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%).
Arms & Interventions
Part 1:FDL176 & FDL169 coadministration
To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
Intervention: FDL176 & FDL169 coadministration
Part 2:FDL176 & FDL169 coadministration
To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
Intervention: FDL176 & FDL169 coadministration
Outcomes
Primary Outcomes
Pharmacokinetic parameters, Cmax
Time Frame: 72 days
The pharmacokinetic parameters of FDL176 when co-administered with FDL169, compared to the pharmacokinetics of FDL176 alone; maximal plasma concentration (Cmax)
Secondary Outcomes
- Incidence of Treatment-Emergent Adverse Events(72 days)